Mavyret (glecaprevir and pibrentasvir), a treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis, shortens the duration of treatment to eight weeks
1 Ottobre 2019
Mavyret (glecaprevir and pibrentasvir) tablets, have now been approved by the FDA for an eight-week duration for the treatment of adults and children ages 12
